Study shows use of EpiSwitch blood test can aid in treatment decision for rheumatoid arthritis

A machine-learning model based on insurance information from amyotrophic lateral sclerosis (ALS) patients may be able to speed diagnosis of the disease in others, research suggests. The findings were presented at the 30th International Symposium on ALS/MND, in the

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, has today announced that it has entered into

Tributes to Pete Frates are continuing to flood in following his death last Monday after an eight-year battle with ALS, showing how the 34-year-old inspiration behind the “Ice Bucket Challenge” was able to touch countless lives

A new study identified a group of sporadic amyotrophic lateral sclerosis (ALS) patients whose disease may arise from a group of “jumping genes” unleashed when TDP-43 protein accumulates in clumps in the brain and spinal cord. These “jumping genes” —

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has announced its final results for the year

The cause of amyotrophic lateral sclerosis (ALS) — a disabling neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to weakened muscles and early death — is not fully understood, but

Our proprietary technology platform enables pharmaceutical companies to accelerate and improve the rate of drug discovery and development Through the development of epigenetic biomarkers, EpiSwitch™ can help pharmaceutical companies to: REDUCE the risk, cost and time to market for therapeutic development programmes GAIN significant insights into

EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”).  CCSs can provide a compelling, stable framework from which changes in the regulation of

Exercise appears to benefit people with amyotrophic lateral sclerosis (ALS) by normalizing molecular changes that occur at the junction of nerves and muscles, but by degrees that depend on the type of exercise, a study in a mouse model of

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers for the pharmaceutical and biotechnology industry, has announced that data yielded by application of its 3D genome architecture technology platform, EpiSwitch™,

Renowned immunologist Iain McInnes has been appointed to the Scientific Advisory Boar of Oxford BioDynamics Plc, where he joins Karol Sikora, Jane Mellor and Lucien Peng-Jin Ooi. McInnes is one of the leading figures in global

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has announced the appointment of Professor Iain McInnes

History  The NHS describes motor neurone disease (MND) as: ‘An uncommon condition that affects the brain and nerves. It causes weakness that gets worse over time.’ The weakness is caused by the deterioration of motor neurons,

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, noted that Mitsubishi Tanabe Pharma America, Inc. has

It has been over 115 years since the Chromosome Theory of Inheritance, the proposal that chromosomes carried the factors of Mendelian inheritance, was articulated by Walter Sutton and Theodor Boveri. Since then, we have seen a

The last decade has seen an explosion in the application of precision medicine strategies in the life science industry, from drug development to clinical trial design. The ability to use molecular tools to identify patients who

Oxford BioDynamics’ (OBD) EpiSwitchTM platform is the first industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs provide a robust, stable framework

Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease